A giant leap for Diabeloop

Grenoble-based startup Diabeloop, which calls the BHT2 building home, has further anchored its position as a pioneer of artificial intelligence for diabetes treatment. The company obtained CE marking for its DBLG1 (a medical device that automates and personalizes the treatment of type 1 diabetes) in 2018. CE marking was obtained for the DBL-hu, for highly unstable diabetes, in 2020.

Diabeloop has been on a roll since November of last year. The startup has entered into three major partnerships to ramp up the international rollout of its solutions. Agreements signed with Terumo Corporation (Japan), SFC Fluidics (United States), and Roche (Switzerland) will help get its self-learning-algorithm-powered devices to patients worldwide. The agreement with Roche, a global leader in integrated diabetes management, will create huge opportunities for Diabeloop across Europe.

Contact: stephanie.jegu@diabeloop.fr

Facebook

Twitter